US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NeOnc Technologies Holdings

6.32

-0.6300-9.06%

Volume:47.69K

Turnover:316.68K

Market Cap:118.47M

PE:-9.16

High:7.00

Open:6.53

Low:5.86

Close:6.95

Loading ...

Overview Company News Filings

NeOnc Technologies announces global patent portfolio totals 176

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

NeOnc Technologies Expects Full Enrollment in Phase 2a Trialfor NEO100-01 by September

MT Newswires Live

BRIEF-Neonc Technologies Holdings Expects Full Enrollment In Promising Phase 2A Trial Of Neo100-01 For Malignant Gliomas In September

Neonc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company’s New President

THOMSON REUTERS

Press Release: NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

NeOnc Technologies Phase 1 Trial Enrollment for NEO212 Brain Cancer Drug Nears Full Enrollment

MT Newswires Live

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

Neonc Technologies Holdings Inc trading resumes

NeOnc Technologies Holdings' Perillyl Alcohol Receives FDA's Rare Pediatric Disease Designation

MT Newswires Live

Neonc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for Neo100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

THOMSON REUTERS

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

BRIEF-NeOnc Technologies Holdings Announces Effectiveness Of Registration Statement And Anticipated Listing Date Of Common Stock On Nasdaq Global Market

Neonc Technologies Holdings, Inc. Appoints DR. Alan Chiang to Its Board of Directors

THOMSON REUTERS

Neonc Technologies Holdings, Inc. Appoints Renowned Neurosurgeon DR. Steven L. Giannotta to Its Board of Directors

THOMSON REUTERS

Neonc Technologies Holdings, Inc. Appoints DR. Victoria Medvec to Board of Directors

THOMSON REUTERS

Press Release: NeOnc Technologies Holdings, Inc. Appoints Dr. Victoria Medvec to Board of Directors

Neonc Technologies Holdings Inc Files for Resale of up to 2.14 Mln Common Shares by Selling Stockholders

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NTHI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NTHI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTHI\",,,,,undefined,":{"symbol":"NTHI","market":"US","secType":"STK","nameCN":"NeOnc Technologies Holdings","latestPrice":6.32,"timestamp":1745265600000,"preClose":6.95,"halted":0,"volume":47685,"delay":0,"floatShares":5219711,"shares":18745865,"eps":-0.69,"marketStatus":"Pre-Mkt","change":-0.63,"latestTime":"04-22 04:22:49 EDT","open":6.53,"high":7,"low":5.86,"amount":316677.5615,"amplitude":0.164029,"askPrice":10.28,"askSize":200,"bidPrice":2.59,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-0.69,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745328600000},"marketStatusCode":1,"adr":0,"listingDate":1711512000000,"exchange":"NASDAQ","adjPreClose":6.43,"postHourTrading":{"tag":"盘后","latestPrice":6.32,"preClose":6.32,"latestTime":"16:05 EDT","volume":2,"amount":12.86,"timestamp":1745265912201},"volumeRatio":0.9003421238329583},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTHI\",,,,,undefined,":{"symbol":"NTHI","floatShares":5219711,"roa":"-189.56%","roe":"--","lyrEps":-0.686076,"volumeRatio":0.9003421238329583,"shares":18745865,"dividePrice":0,"high":7,"amplitude":0.164029,"preClose":6.95,"low":5.86,"week52Low":5.86,"pbRate":"-21.52","psRate":"1427.40","week52High":25,"institutionHeld":0,"latestPrice":6.32,"committee":-0.333333,"eps":-0.69,"divideRate":0,"volume":47685,"delay":0,"ttmEps":-0.69,"open":6.53,"prevYearClose":25,"prevWeekClose":6.95,"prevMonthClose":13.36,"prevQuarterClose":13.36,"fiveDayClose":9.04},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NTHI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527415751","title":"NeOnc Technologies announces global patent portfolio totals 176","url":"https://stock-news.laohu8.com/highlight/detail?id=2527415751","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527415751?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:35","pubTimestamp":1744720548,"startTime":"0","endTime":"0","summary":"NeOnc Technologies (NTHI) announced that its global patent portfolio totals 176, reinforcing its competitive position. The Company’s IP portfolio, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neonc-technologies-announces-global-patent-portfolio-totals-176?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neonc-technologies-announces-global-patent-portfolio-totals-176?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2527418493","title":"NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2527418493","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527418493?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:05","pubTimestamp":1744718700,"startTime":"0","endTime":"0","summary":"-- 176 Patents Issued and Outstanding Reinforces NeOnc’s Competitive Position -- CALABASAS, Calif., April  15, 2025  (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a biopharmace","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/15/3061691/0/en/NeOnc-Technologies-Global-Patent-Portfolio-Covers-Core-Pipeline-Across-All-Major-Pharmaceutical-Markets.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2527194992","title":"NeOnc Technologies Expects Full Enrollment in Phase 2a Trialfor NEO100-01 by September","url":"https://stock-news.laohu8.com/highlight/detail?id=2527194992","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527194992?lang=en_us&edition=fundamental","pubTime":"2025-04-14 23:34","pubTimestamp":1744644866,"startTime":"0","endTime":"0","summary":"NeOnc Technologies  said Monday it expects full enrollment in a phase 2a trial for its therapeutic candidate NEO100-01 by September, with just six patients remaining to reach the 25-patient target.The trial is evaluating NEO100, which is intended for the treatment of malignant gliomas, particularly IDH1 mutant Grade III and IV astrocytomas. The read-out for the trial's data is expected early next year, the company said.The drug candidate has been granted orphan drug and fast-track status by the US Food and Drug Administration, according to the company.Price: 8.64, Change: -0.27, Percent Change: -3.03","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2527608591","title":"BRIEF-Neonc Technologies Holdings Expects Full Enrollment In Promising Phase 2A Trial Of Neo100-01 For Malignant Gliomas In September","url":"https://stock-news.laohu8.com/highlight/detail?id=2527608591","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527608591?lang=en_us&edition=fundamental","pubTime":"2025-04-14 22:10","pubTimestamp":1744639839,"startTime":"0","endTime":"0","summary":"BRIEF-Neonc Technologies Holdings Expects Full EnrollmentIn Promising Phase 2A Trial Of Neo100-01 For Malignant GliomasIn SeptemberApril 14 (Reuters) - Neonc Technologies Holdings Inc NTHI.O:NEONC TEC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nTUA30XSJQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"gpt_icon":0},{"id":"2526563198","title":"Neonc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company’s New President","url":"https://stock-news.laohu8.com/highlight/detail?id=2526563198","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526563198?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:05","pubTimestamp":1744286700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nTUABJRR2Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NTHI"],"gpt_icon":0},{"id":"2526631975","title":"Press Release: NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President","url":"https://stock-news.laohu8.com/highlight/detail?id=2526631975","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526631975?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:05","pubTimestamp":1744286700,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President. CALABASAS, Calif., April 10, 2025  -- NeOnc Technologies Holdings, Inc. , a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system  cancers and disorders, today announced that Executive Chairman Amir Heshmatpour has been appointed to serve as President of the Company. Heshmatpour will retain his role as Executive Chairman, while taking on day-to-day leadership responsibilities to accelerate the Company's strategic and clinical initiatives.\"Amir's appointment as President reflects our commitment to strong, visionary leadership as NeOnc advances its clinical programs,\" said Dr. Thomas Chen, CEO of NeOnc. \"His extensive experience in building and scaling companies, coupled with his deep understanding of capital markets and business development, will be instrumental as we move forward.\"","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4555","BK4588","CNS","BK4135","BK4585","BK4099","03160","BK4007","BK4604","TM"],"gpt_icon":0},{"id":"2526082335","title":"NeOnc Technologies Phase 1 Trial Enrollment for NEO212 Brain Cancer Drug Nears Full Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2526082335","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526082335?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:39","pubTimestamp":1744144774,"startTime":"0","endTime":"0","summary":"NeOnc Technologies  said Tuesday that its phase 1 trial of NEO212 for the treatment of brain cancer is nearing full enrollment.The final group is expected to complete the study's dosing protocol, the company said, adding that the NEO212 trial protocol has five escalating groups with three patients per group.NEO212 is a combination of temozolomide, which is the current standard-of-care chemotherapy for malignant gliomas, and perillyl alcohol, NeOnc said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2526840453","title":"NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2526840453","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526840453?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:05","pubTimestamp":1744142700,"startTime":"0","endTime":"0","summary":"CALABASAS, Calif., April  08, 2025  (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervou","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057991/0/en/NeOnc-Technologies-Announces-Near-Completion-of-Phase-I-Enrollment-for-NEO212-Brain-Cancer-Therapy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI","CNS","BK4135"],"gpt_icon":0},{"id":"2524200962","title":"Neonc Technologies Holdings Inc trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2524200962","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524200962?lang=en_us&edition=fundamental","pubTime":"2025-04-04 21:51","pubTimestamp":1743774684,"startTime":"0","endTime":"0","summary":"09:45 EDT Neonc Technologies (NTHI) Holdings Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving break...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neonc-technologies-holdings-inc-trading-resumes-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neonc-technologies-holdings-inc-trading-resumes-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NTHI"],"gpt_icon":0},{"id":"2523094049","title":"NeOnc Technologies Holdings' Perillyl Alcohol Receives FDA's Rare Pediatric Disease Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2523094049","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523094049?lang=en_us&edition=fundamental","pubTime":"2025-03-31 22:03","pubTimestamp":1743429808,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings (NTHI) said Monday that the US Food and Drug Administration has granted rare pediatric disease designation to perillyl alcohol, also known as NEO100, for the treatment of p","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2523945688","title":"Neonc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for Neo100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2523945688","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523945688?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:05","pubTimestamp":1743422700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA7CBTM8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2523221945","title":"NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2523221945","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523221945?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:05","pubTimestamp":1743422700,"startTime":"0","endTime":"0","summary":"WESTLAKE VILLAGE, Calif., March  31, 2025  (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ Global Market: NTHI), a clinical-stage medical biotechnology company, today announced that the ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052251/0/en/NeOnc-Technologies-Holdings-Inc-Receives-Rare-Pediatric-Disease-Designation-for-NEO100-in-Treatment-of-Pediatric-Type-Diffuse-High-Grade-Gliomas.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"gpt_icon":0},{"id":"2522350708","title":"BRIEF-NeOnc Technologies Holdings Announces Effectiveness Of Registration Statement And Anticipated Listing Date Of Common Stock On Nasdaq Global Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2522350708","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522350708?lang=en_us&edition=fundamental","pubTime":"2025-03-26 05:27","pubTimestamp":1742938029,"startTime":"0","endTime":"0","summary":"BRIEF-NeOnc Technologies Holdings Announces Effectiveness Of Registration Statement And Anticipated Listing Date Of Common Stock On Nasdaq Global MarketMarch 25 (Reuters) - Neonc Technologies Holdings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUABHNG9K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI"],"gpt_icon":0},{"id":"2522076118","title":"Neonc Technologies Holdings, Inc. Appoints DR. Alan Chiang to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522076118","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522076118?lang=en_us&edition=fundamental","pubTime":"2025-03-25 21:00","pubTimestamp":1742907602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUADXLY2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI"],"gpt_icon":0},{"id":"2522276540","title":"Neonc Technologies Holdings, Inc. Appoints Renowned Neurosurgeon DR. Steven L. Giannotta to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522276540","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522276540?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:15","pubTimestamp":1742904900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUA4KMQBD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI"],"gpt_icon":0},{"id":"2522024067","title":"Neonc Technologies Holdings, Inc. Appoints DR. Victoria Medvec to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522024067","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522024067?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:00","pubTimestamp":1742904000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUA9RX8RQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI"],"gpt_icon":0},{"id":"2522022507","title":"Press Release: NeOnc Technologies Holdings, Inc. Appoints Dr. Victoria Medvec to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522022507","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522022507?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:00","pubTimestamp":1742904000,"startTime":"0","endTime":"0","summary":"Dr. Medvec adds extensive knowledge of high-stakes issues including mergers and acquisitions and partnerships to the NeOnc team. WESTLAKE VILLAGE, Calif., March 25, 2025  -- NeOnc Technologies Holdings, Inc. , a clinical-stage medical biotechnology company, announced today that Dr. Victoria Medvec, has been appointed to its Board of Directors. Dr. Medvec is the Chief Executive Officer of Medvec and Associates, a valued adviser to executives and boards at a substantial portion of Fortune 100 companies.Dr. Medvec holds the Adeline Barry Davee Professorship of Management and Organizations at Northwestern University's Kellogg School of Management, where she has been a distinguished faculty member since 1995. She is the co-founder of the Kellogg Center for Executive Women. Her research has garnered attention from prestigious publications such as the Wall Street Journal, the New York Times, the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NTHI","BK4099","BK4604","BK4555","03160","BK4585","TM","BK4095","VCCTF"],"gpt_icon":0},{"id":"2500821199","title":"Neonc Technologies Holdings Inc Files for Resale of up to 2.14 Mln Common Shares by Selling Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2500821199","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500821199?lang=en_us&edition=fundamental","pubTime":"2025-01-03 19:08","pubTimestamp":1735902526,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250103:nFWN3NY0T7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NTHI\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NTHI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NTHI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NTHI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NTHI","date":"2025-04-17","current":-11.028403,"percent":0.9375,"low":-26.074295,"twenty":-19.044476,"median":-15.392499,"eighty":-12.855967,"high":-11.028403,"avg":-16.351317,"sd":3.867449,"marketCap":131221055},"quantilePoints":[{"date":"2024-03-28","current":-18.899455,"twenty":-18.899455,"median":-18.899455,"eighty":-18.899455,"marketCap":282000000},{"date":"2025-03-28","current":-18.905834,"twenty":-19.009816,"median":-18.905834,"eighty":-18.902007,"marketCap":224950380},{"date":"2025-04-04","current":-15.093157,"twenty":-20.260752,"median":-18.902645,"eighty":-16.151884,"marketCap":179585386},{"date":"2025-04-11","current":-14.179375,"twenty":-19.504518,"median":-17.739974,"eighty":-15.124667,"marketCap":168712785},{"date":"2025-04-17","current":-11.028403,"twenty":-19.044476,"median":-15.392499,"eighty":-12.855967,"marketCap":131221055}],"updateTime":1745285727922}}}